Genmab A/S is a Danish biotechnology company that develops monoclonal antibodies to treat cancer and other diseases, including multiple myeloma, thyroid eye disease, chronic lymphocytic leukemia, and several types of solid tumors. Their product portfolio includes several drugs like DARZALEX, teprotumumab, ofatumurnab, and Amivantamab. The company also has a number of products in pre-clinical development and collaboration agreements with other biotech firms.